Avant Sells $61 Million in Rights of Rotarix Sales

Avant Immunotherapeutics will raise up to $61 million by selling a stake in the net royalties it expects from a vaccine that helps prevent severe diarrhea in young children. The Needham company said it entered into an agreement with Paul Royalty Fund II LP, to sell up to a $61 million in interest in the net royalties Avant expects from global sales of its Rotarix vaccine. Avant will get $50 million from the deal over the next year.
Boston Business Journal